Health care costs associated with the management of comorbidities and thrombotic complications account for a large portion of health care expenditures in patients with myeloproliferative neoplasms (MPNs), according to results of a population-based, retrospective study. These findings were published in Leukemia and Lymphoma.1
MPNs, including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are defined as a group of Philadelphia chromosome-negative diseases that involve excess production of cells in the bone marrow. Although overall healthcare utilization costs for patients with MPNs has been reported to be 2 to 6 times higher compared with the general US population based on studies of people enrolled in Medicare, only limited information is available regarding the specific types of health care expenditures involved.
This match-cohort study involved an analysis of adult patients with MPNs compared with the general adult population included in the Ontario Cancer Registry from January 1, 2004, to December 31, 2016. Each patient case of MPN was matched with 4 control participants based on age, sex, geographic location, and neighborhood income, with the index date of MPN diagnosis also used as the index date for the matched controls. All participants were followed until December 31, 2017, or date of death.
Data were collected on the average lengths of stay in the hospital and intensive care unit (ICU), long-term care, and the average number of outpatient visits with general practitioners and specialists, as well as emergency department (ED) and home care visits. Baseline patient and healthcare utilization characteristics corresponded to those reported within 2 years of the index date. Baseline comorbidity was represented by the Johns Hopkins Aggregated Diagnosis Group (ADG) score, with higher scores representing greater comorbidity burden.2